Transforming the treatment of Classical Complement-Mediated Disease
Annexon Biosciences is creating and developing proprietary therapeutic products that modulate the classical complement pathway. Our pipeline is based on breakthrough research showing that the initiating molecule of the classical pathway, C1q, stimulates an immune-mediated attack that causes cell loss and tissue damage in a broad array of autoimmune, neurodegenerative and ophthalmic disorders.
Experience + Expertise
Backed by a team with deep experience in autoimmune and neurodegenerative diseases, our mission is to rapidly advance disease-modifying therapeutics for patients with complement-mediated autoimmune and neurodegenerative disorders.